SCHEMBL6531263

SCHEMBL6531263

COc1ccc(/C=C/c2nc(-c3ccc(Cl)cc3Cl)c[nH]2)cc1.COc1ccc(CCc2nc(-c3ccc(Cl)cc3Cl)c[nH]2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 2/20 0.42
RELA Q04206 2/20 0.38
AHR P35869 1/20 0.38
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.37
IDO1 P14902 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
CRHR1 P34998 1/20 0.36
CNR1 P21554 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
NPC1 O15118 1/20 0.35
LMNA P02545 1/20 0.35
HPGD P15428 1/20 0.35
ALOX12 P18054 1/20 0.35
NFKB1 P19838 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6531265 1.00 CXCR2 (0.42) CXCR2RELAAHRMAPTKDM4E
SCHEMBL1480448 0.90 RELA (0.46) CXCR2RELAAHRMAPTKDM4E
SCHEMBL1480451 0.90 RELA (0.46) CXCR2RELAAHRMAPTKDM4E
SCHEMBL1480745 0.90 CXCR2 (0.49) CXCR2MAPTIDO1CA12CA1
SCHEMBL1481070 0.87 MAPT (0.44) CXCR2RELAAHRMAPTKDM4E
SCHEMBL1481066 0.87 MAPT (0.44) CXCR2RELAAHRMAPTKDM4E
SCHEMBL1481308 0.84 RELA (0.41) CXCR2RELAAHRMAPTKDM4E
SCHEMBL1481310 0.84 RELA (0.41) CXCR2RELAAHRMAPTKDM4E
SCHEMBL1483642 0.84 RELA (0.41) CXCR2RELAAHRMAPTKDM4E
SCHEMBL1676226 0.84 CXCR2 (0.47) CXCR2MAPTIDO1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004071447-A9 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC (US) 2005-10-13 WO disclosed